R. Isaacs

发表

Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial

C. Katlama, J. Gatell, A. Lazzarin, 2007, The Lancet.

Residual human immunodeficiency virus (HIV) Type 1 RNA and DNA in lymph nodes and HIV RNA in genital secretions and in cerebrospinal fluid after suppression of viremia for 2 years.

D. Richman, H. Günthard, S. Frost, 2001, The Journal of infectious diseases.

Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials.

B. Clotet, C. Katlama, J. Gatell, 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Safety and tolerability of ertapenem.

H. Teppler, A. Meibohm, G. Herman, 2004, The Journal of antimicrobial chemotherapy.

Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial.

S. Hammer, J. Montaner, D. Cooper, 2001, JAMA.

Sustained Antiretroviral Effect of Raltegravir After 96 Weeks of Combination Therapy in Treatment-Naive Patients With HIV-1 Infection

C. Crumpacker, C. Kovacs, R. Danovich, 2009, Journal of acquired immune deficiency syndromes.

Effects of omeprazole on plasma levels of raltegravir.

H. Teppler, J. Wagner, B. Nguyen, 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults: combined analysis of two multicentre randomized, double-blind studies.

G. Woods, R. Isaacs, N. Vetter, 2004, The Journal of antimicrobial chemotherapy.

Ertapenem, the first of a new group of carbapenems.

R. Isaacs, P. Shah, 2003, The Journal of antimicrobial chemotherapy.

Plasma and Intrapulmonary Concentrations of ETX2514 and Sulbactam following Intravenous Administration of ETX2514SUL to Healthy Adult Subjects

R. Isaacs, K. Rodvold, M. Gotfried, 2018, Antimicrobial Agents and Chemotherapy.

Raltegravir with optimized background therapy for resistant HIV-1 infection.

D. Hazuda, B. Clotet, C. Katlama, 2008, The New England journal of medicine.

Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100-week follow-up.

D. Richman, D. Havlir, J. Mellors, 1998, JAMA.

Antiretroviral Activity, Pharmacokinetics, and Tolerability of MK-0518, a Novel Inhibitor of HIV-1 Integrase, Dosed As Monotherapy for 10 Days in Treatment-Naive HIV-1-Infected Individuals

C. Kovacs, D. Cooper, R. Steigbigel, 2006, Journal of acquired immune deficiency syndromes.

Rapid and Durable Antiretroviral Effect of the HIV-1 Integrase Inhibitor Raltegravir as Part of Combination Therapy in Treatment-Naive Patients With HIV-1 Infection: Results of a 48-Week Controlled Study

C. Crumpacker, C. Kovacs, H. Teppler, 2007, Journal of acquired immune deficiency syndromes.

Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection.

D. Hazuda, B. Clotet, C. Katlama, 2008, The New England journal of medicine.

Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial.

Jing Zhao, Christine Katlama, Benjamin Young, 2011, The Lancet. Infectious diseases.

3-Year Suppression of HIV Viremia with Indinavir, Zidovudine, and Lamivudine

J. Mellors, J. Condra, J. Chodakewitz, 2000, Annals of Internal Medicine.

Raltegravir: the first HIV‐1 integrase strand transfer inhibitor in the HIV armamentarium

D. Hazuda, R. Leavitt, H. Teppler, 2011, Annals of the New York Academy of Sciences.

Six-year follow-up of HIV-1-infected adults in a clinical trial of antiretroviral therapy with indinavir, zidovudine, and lamivudine

D. Richman, D. Havlir, J. Mellors, 2003, AIDS.

Pathogen-Targeted Clinical Development to Address Unmet Medical Need: Design, Safety, and Efficacy of the ATTACK Trial

Bin Du, R. Watkins, R. Isaacs, 2023, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Pharmacokinetics and Tolerability of Intravenous Sulbactam-Durlobactam with Imipenem-Cilastatin in Hospitalized Adults with Complicated Urinary Tract Infections, Including Acute Pyelonephritis

R. Isaacs, Alita A. Miller, R. Fomkin, 2019, Antimicrobial Agents and Chemotherapy.

Pharmacokinetics, Safety, and Tolerability of Intravenous Durlobactam and Sulbactam in Subjects with Renal Impairment and Healthy Matched Control Subjects

R. Preston, R. Isaacs, J. O’Donnell, 2019, Antimicrobial Agents and Chemotherapy.

Long-Term Efficacy and Safety of the HIV Integrase Inhibitor Raltegravir in Patients With Limited Treatment Options in a Phase II Study

C. Katlama, J. Gatell, A. Lazzarin, 2010, Journal of acquired immune deficiency syndromes.

Safety, Pharmacokinetics, and Drug-Drug Interaction Potential of Intravenous Durlobactam, a β-Lactamase Inhibitor, in Healthy Subjects

R. Isaacs, J. O’Donnell, K. Lawrence, 2020, Antimicrobial Agents and Chemotherapy.

Efficacy and safety of sulbactam-durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii-calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK).

R. Wunderink, K. Kaye, A. Shorr, 2023, The Lancet. Infectious diseases.